BPT CLINICAL; INTERNAL MEDICINE CLINICAL ONCOLOGY EXAM 2026 QUESTIONS AND 100% CORRECT AND VERIFIED ANSWERS GRADED A+

Criteria for evaluating the therapeutic response during treatment of cancer patients: A) Dukes-staging system B) RECIST-staging system C) Forrest-staging system D) Bismuth-staging system E) All of the above B) RECIST-staging system Dukes classification is used for the staging of colorectal carcinoma. RECIST (Response Evaluation Criteria In Solid Tumors) is used for evaluating the therapeutic response in solid tumors. In case of a gastroduodenal ulcer disease, Forrest classification is used to evaluate the bleeding activity of the ulcer. Bismut-classification aims to provide an anatomical description of hilar biliary tract cancers. • 10 INT - 17.12 In oncological clinical studies progression free survival (PFS) is often evaluated. How do you define this term? A) Progression-Free Survival (PFS) is the time that elapses in a progressive/metastatic tumor from starting treatment (from clinical trial randomization) to repeated tumor growth and/or death of a patient. B) PFS is the time that elapses from the onset of the therapy of an advanced / metastatic disease (in clinical trials from randomization) to the death of a patient. A) Progression-Free Survival (PFS) is the time that elapses in a progressive/metastatic tumor from starting treatment (from clinical trial randomization) to repeated tumor growth and/or death of a patient. The FDA (Food and Drug Administration, United States Department of Food and Drug Administration) issued detailed guidelines on the clinical endpoint of oncological clinical trials. Progression-free survival ranges from treatment initiation, i.e. randomization to objective tumor progression or to the patient’s death. (TTP, time-to-pregression: only time to progression is observed, death of patients is not taken into account, censorship of mortality data by terminology.) • 11 INT - 17.13 Definition of overall survival (OS): A) Overall Survival (OS) is the time that elapses in a progressive / metastatic tumor from starting treatment (from randomization in clinical trials) to repeatedly confirmed tumor growth and / or death of the patient. B) Overall survival (OS) is the time that elapses from the onset of tumor treatment (in clinical trials from randomization) to the death of a patient. B) Overall survival (OS) is the time that elapses from the onset of tumor treatment (in clinical trials from randomization) to the death of a patient. The FDA (Food and Drug Administration, United States Department of Food and Drug Administration) issued detailed guidelines on the clinical endpoint of oncology clinical trials. (The Clinical Trial Endpoints for the Approval of Cancer Drugs and Biology, 2007) Overall survival (OS) according to the guidelines, is the time elapsed from randomization (that is, the commencement of a trial after randomized election of patients) until patients’ death from any reason. This is a very realistic endpoint in oncology clinical trials. It is accurate, easy to measure and document, and is therefore a preferred endpoint in oncology clinical trials.